Literature DB >> 10882596

Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses.

M Yamamoto1, H Kiyono, M N Kweon, S Yamamoto, K Fujihashi, H Kurazono, K Imaoka, H Bluethmann, I Takahashi, Y Takeda, M Azuma, J R McGhee.   

Abstract

In an in vitro study, Escherichia coli heat-labile toxin (LT) was shown to directly affect activated CD4(+) T cells and support interleukin (IL)-5 production in IL-4-deficient (IL-4(-/-)) mice, whereas cholera toxin (CT) did not. Both LT and CT enhanced B7-2 expression on B cells and macrophages. These effects were not influenced by CD40-CD40 ligand cosignaling. Addition of LT- or CT-treated antigen-presenting cells to anti-CD3-triggered CD4(+) T cells resulted in the induction of T cell proliferative responses. Further, these responses were inhibited by anti-B7-2 monoclonal antibody. Cocultivation of CD4(+) T cells with LT- or CT-treated antigen-presenting cells and anti-CD3 enhanced Th1- and IL-4-mediated Th2-type cytokine production. The results from in vitro studies were supported by in vivo studies in IL-4(-/-) mice, in which LT induced mucosal IgA responses but CT did not. Thus, although both LT and CT induce mucosal adjuvant responses via IL-4-dependent Th2-type responses, LT also elicits Th1- and IL-4-independent Th2-type responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882596     DOI: 10.1086/315694

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

3.  Gut T cell receptor-γδ(+) intraepithelial lymphocytes are activated selectively by cholera toxin to break oral tolerance in mice.

Authors:  C P Frossard; K E Asigbetse; D Burger; P A Eigenmann
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

4.  The presence of CD209 expressing dendritic cells correlates with biofilm positivity in chronic rhinosinusitis with nasal polyposis.

Authors:  Tamás Karosi; Péter Csomor; Zoltán Hegyi; István Sziklai
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-29       Impact factor: 2.503

5.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

6.  Increased antigen specific T cell numbers in the absence of altered migration or division rates as a result of mucosal cholera toxin administration.

Authors:  Maria Kaparakis-Liaskos; Michelle D Tate; Jason D Price; Martin Pearse; Odilia L C Wijburg
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

7.  Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.

Authors:  Håvard Jakobsen; Stefania Bjarnarson; Giuseppe Del Giudice; Monique Moreau; Claire-Anne Siegrist; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

Review 9.  Novel adjuvants & delivery vehicles for vaccines development: a road ahead.

Authors:  Teena Mohan; Priyanka Verma; D Nageswara Rao
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.